JAZZ Jazz Pharmaceuticals plc

142.59
+2.85  (+2%)
Previous Close 139.74
Open 140.67
52 Week Low 86.88
52 Week High 154.24
Market Cap $7,907,846,194
Shares 55,458,631
Float 52,370,084
Enterprise Value $8,398,079,700
Volume 622,232
Av. Daily Volume 835,222
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
PF743 (JZP-458)
Acute lymphoblastic leukemia (ALL)
BLA Filing
BLA Filing
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
Defibrotide
acute Graft-versus-Host-Disease (aGvHD)
Phase 2
Phase 2
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Drug Pipeline

Drug Stage Notes
JZP-385
Essential Tremor
Phase 2
Phase 2
Phase 2b trial to be initiated early-2021.
Xywav
Cataplexy and Excessive Daytime Sleepiness in Narcolepsy
Approved
Approved
FDA Approval announced July 22, 2020.
Lurbinectedin
Small cell lung cancer (SCLC)
Approved
Approved
FDA Approval announced June 15, 2020.
Defibrotide
VOD in high-risk patients following hematopoietic stem cell transplantation
Phase 3
Phase 3
Phase 3 trial stopped early due to lack of efficacy.
Solriamfetol (JZP-110)
Excessive daytime sleepiness (EDS) in major depressive disorder
Phase 3
Phase 3
Phase 3 trial to commence mid-2020.
Solriamfetol (JZP-110)
Excessive sleepiness associated with narcolepsy
Approved
Approved
FDA Approval announced March 20, 2019.
JZP-258
Idiopathic Hypersomnia
Phase 3
Phase 3
Phase 3 enrolment to be completed 2H 2020.
Vyxeos in combination with venetoclax
First-line unfit Acute myeloid leukemia
Phase 1b
Phase 1b
Phase 1b ongoing.
Defibrotide
CAR-T associated neurotoxicity in diffuse large B-cell lymphoma (DLBCL) patients
Phase 2
Phase 2
Phase 2 commencement of enrolment announced October 10, 2019.
Xyrem
Pediatric narcolepsy patients with cataplexy
Approved
Approved
FDA Approval announced October 26, 2018.
Vyxeos
Acute myeloid leukemia
Approved
Approved
Approval announced August 3, 2017.
JZP-110
Excessive sleepiness associated with obstructive sleep apnea
Phase 3
Phase 3
Phase 3 data released March 20, 2017 - primary endpoints met.
JZP-6
Fibromyalgia
Approved
Approved
CRL received October 11, 2010.

Latest News

  1. DUBLIN, Sept. 17, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced the launch of Find the Right Fit (FindTheRightFit-sAML.com), a U.S. patient education program developed in consultation with the Myelodysplastic Syndromes (MDS) Foundation, Inc. and the Cancer Support Community focused on empowering people affected by secondary acute myeloid leukemia (sAML) and MDS.

    Within the hematology oncology community, certain patient groups face especially difficult odds. In particular, patients newly diagnosed with sAML and related blood disorders have few resources focused on disease education and managing daily life that are dedicated to this community. As a subtype of AML, which has the lowest survival rate of all leukemias…

    DUBLIN, Sept. 17, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced the launch of Find the Right Fit (FindTheRightFit-sAML.com), a U.S. patient education program developed in consultation with the Myelodysplastic Syndromes (MDS) Foundation, Inc. and the Cancer Support Community focused on empowering people affected by secondary acute myeloid leukemia (sAML) and MDS.

    Within the hematology oncology community, certain patient groups face especially difficult odds. In particular, patients newly diagnosed with sAML and related blood disorders have few resources focused on disease education and managing daily life that are dedicated to this community. As a subtype of AML, which has the lowest survival rate of all leukemias1, sAML has a particularly poor prognosis.2,3

    "During Blood Cancer Awareness Month, we reflect on the unwavering strength of patients, caregivers, families and healthcare providers battling or impacted by blood cancer," said Kim Sablich, executive vice president and general manager of North America at Jazz Pharmaceuticals. "Find the Right Fit was created with the understanding that an sAML diagnosis can be overwhelming, but that education can help inform optimal treatment plans that work best for each individual patient."

    Find the Right Fit—Nagivating sAML offers patients and their caregivers a powerful collection of tools, including articles, videos, and patient stories, intended to educate on the science behind sAML, provide information on which subtypes patients should be tested for, and offer resources regarding treatment options and coping strategies. The program also shares the stories of patients, which are featured to help those impacted by sAML relate to the various experiences and perspectives that exist within the community.

    "In addition to the support available through the Cancer Support Community and the Myelodysplastic Syndrome Foundation, Inc., we are pleased that Find the Right Fit adds resources and information to help inform and inspire people during this critical point in time," said Linda Bohannon, MSM, BSN, RN, president of the Cancer Support Community.

    Making up approximately 30 percent of AML cases, sAML can spread quickly and requires a specialized treatment approach, which is why it is important that patients know what to discuss with their doctors in order to pursue the route best suited for their unique needs.3-7 By listening to advocacy groups, patients and their care teams, Jazz hopes to continue evolving the Find the Right Fit program to better serve those living with an sAML or MDS diagnosis.

    "With 16 years of experience at the MDS Foundation, I understand how overwhelming a cancer diagnosis can be for a family," said Tracey Iraca, executive director of the MDS Foundation, Inc. "The foundation is proud to partner with Jazz on the launch of Find the Right Fit – Navigating sAML, to help provide patients with vital information to navigate a rare disease diagnosis."

    About AML

    Acute myeloid leukemia (AML) is a type of cancer in which the bone marrow makes abnormal myeloblasts (a type of white blood cell), red blood cells, or platelets.3 It can sometimes spread to other parts of the body including the lymph nodes, liver, spleen, central nervous system (brain and spinal cord), and testicles.8 AML is a relatively rare disease representing 1.1 percent of all new cancer cases.9 It is estimated that more than 19,500 people will be diagnosed with AML in the United States this year with the potential for more than 11,000 people to die from the disease.10 The median age at diagnosis is 68 years old,9 with rising age associated with a progressively worsening prognosis.11 There is also a reduced tolerance for intensive chemotherapy as patients age.12 AML has the lowest survival rate of any other form of leukemia.9 Patients with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes may have a particularly poor prognosis.13-15  A hematopoietic stem cell transplant may be a curative treatment option for patients.16

    About Jazz Pharmaceuticals

    Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is a global biopharmaceutical company dedicated to developing and commercializing life-changing medicines that transform the lives of patients with serious diseases - often with limited or no options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in key therapeutic areas. Our focus is in neuroscience, including sleep and movement disorders, and in oncology, including hematologic malignancies and solid tumors. We actively explore new options for patients including novel compounds, small molecule advancements, biologics and innovative delivery technologies. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in more than 90 countries. For more information, please visit www.jazzpharmaceuticals.com and follow @JazzPharma on Twitter.

    About the MDS Foundation

    The MDS Foundation, Inc. is an international non-profit advocacy organization whose mission is to support and educate patients and healthcare providers with innovative research into the fields of MDS, Acute Myeloid Leukemia and related myeloid neoplasms in order to accelerate progress leading to the diagnosis, control and cure of these diseases.

    About the Cancer Support Community

    As the largest professionally led nonprofit network of cancer support worldwide, the Cancer Support Community (CSC) is dedicated to ensuring that all people impacted by cancer are empowered by knowledge, strengthened by action and sustained by community. This global network of 175 locations, including CSC and Gilda's Club centers, healthcare partnerships and satellite locations, delivers more than $50 million in free support services to patients and families.

    Media Contact:

    Jacqueline Kirby, Vice President, Corporate Affairs & Government Relations

    Ireland +353 1 697 2141        

    U.S. +1 215 867 4910

    Investor Contact:

    Kathee Littrell, Vice President, Investor Relations

    Ireland +353 1 634 7887        

    U.S. +1 650 496 2717

    References:

    1. Leukemia & Lymphoma Society. Updated data on blood cancers. 2019-2020. https://llsorg.prod.acquia-sites.com/sites/default/files/file_assets/PS80%20Facts_Book_2019-20_FINAL.pdf. Accessed September 1, 2020.
    2. Granfeldt Østgård LS, Medeiros BC, Sengeløv H, et al. Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study. J Clin Oncol. 2015;33(31):3641-3649.
    3. National Cancer Institute. Adult acute myeloid leukemia treatment (PDQ®) – patient version. https://www.cancer.gov/types/leukemia/patient/adult-aml-treatment-pdq. Updated March 6, 2020. Accessed September 1, 2020.  
    4. Nagel G, Weber D, Fromm E, et al. German Austrian AML Study Group (AMLSG). Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO). Ann Hematol. 2017;96(12):1993-2003.
    5. Leone G, Mele L, Pulsoni, A, et al. The incidence of secondary leukemias. Haematologica. 1999;84(10):937-945.
    6. Cheung E, Perissinotti AJ, Bixby DL, et al. The leukemia strikes back: a review of pathogenesis and treatment of secondary AML. Ann Hematol. 2019;98(3):541-559.
    7. DiNardo CD, Cortes JE. Mutations in AML: prognostic and therapeutic implications. Hematology Am Soc Hematol Educ Program. 2016;1:348–355.
    8. American Cancer Society. What is acute myeloid leukemia (AML)? https://www.cancer.org/cancer/acute-myeloid-leukemia/about/what-is-aml.html.  Updated August 21, 2018. Accessed September 1, 2020.
    9. SEER Stat Facts: AML. 2020.
    10. American Cancer Society. Key statistics for acute myeloid leukemia (AML). https://www.cancer.org/cancer/acute-myeloid-leukemia/about/key-statistics.html. Updated January 8, 2020. Accessed August 26, 2020.
    11. Baer MR, George SL, Larson RA et al. Leukemia. 2011 May;25(5):10.1038/eu.2011.9.
    12. Klepin HD. Hematology Am Soc Hematol Educ Program. 2014;2014(1):8-13.
    13. Goldstone AH, Burnett AK, Avivi I et al. Secondary acute myeloid leukemia has a worse outcome than de novo AML, even taking into account cytogenetics and age. AML 10, 11, 12 MRC Trials. Blood. 2002;100(88a):(Abstr 322).
    14. Schiller GJ. Hematol Educ Program. 2013:201-208.
    15. Kern W, Haferlach T, Schnittger S, Hiddemann W, Schoch C. Prognosis in therapy-related acute myeloid leukemia and impact of karyotype. J Clin Oncol. 2004 Jun 15;22(12):2510-1.
    16. Peccatori, J and Ciceri, F. Haematologica. 2010 Jun; 95(6):857–859. doi:0.3324/haematol.2010.023184.

    Jazz Pharmaceuticals Logo (PRNewsFoto/Jazz Pharmaceuticals plc) (PRNewsFoto/Jazz Pharmaceuticals plc)

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/jazz-pharmaceuticals-launches-initiative-to-help-educate-people-living-with-rare-form-of-leukemia-301133085.html

    SOURCE Jazz Pharmaceuticals plc

    View Full Article Hide Full Article
  2. DUBLIN, Sept. 15, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced its support of the American Heart Association's sleep health educational content aimed at improving the health and well-being of those struggling with healthy sleep or those living with sleep disorders. As part of the initiative, the Association, with financial support from Jazz, will create educational multimedia content that will be available at www.heart.org/en/health-topics/sleep-disorders.

    Studies show that more than one-third of Americans do not get the recommended seven hours of sleep per night.1,2 Jazz and the Association seek to reverse this trend, as it is well established that sleep disorders and disrupted sleep can put people at higher risk…

    DUBLIN, Sept. 15, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced its support of the American Heart Association's sleep health educational content aimed at improving the health and well-being of those struggling with healthy sleep or those living with sleep disorders. As part of the initiative, the Association, with financial support from Jazz, will create educational multimedia content that will be available at www.heart.org/en/health-topics/sleep-disorders.

    Studies show that more than one-third of Americans do not get the recommended seven hours of sleep per night.1,2 Jazz and the Association seek to reverse this trend, as it is well established that sleep disorders and disrupted sleep can put people at higher risk for cardiometabolic diseases, including obesity, diabetes, heart attack, stroke and coronary artery disease.3,4 Adequate, healthy sleep is linked to getting sick less often, staying at a healthy weight, reducing stress and thinking more clearly.5

    "Jazz's purpose is to innovate to transform the lives of patients, and the American Heart Association's consumer education aims to positively affect the lives of people struggling with healthy sleep or sleep disorders," said Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals. "We are proud to support the American Heart Association to educate and empower Americans to live healthier lives through the power of sleep with an emphasis on sleep disorders, comorbidities and well-being. At Jazz, we are committed to maximizing our social impact and working with like-minded organizations to best serve our communities."

    Through Jazz's financial support, the American Heart Association will create content to educate those living with sleep disorders, their loved ones and the general public. The content will include a series of podcasts featuring experts discussing sleep, sleep disorders and comorbidities associated with poor sleep.

    "For nearly 100 years, the American Heart Association has been fighting heart disease and stroke, working to be a relentless force for a world of longer, healthier lives," said Eduardo Sanchez, M.D., M.P.H., FAAFP, chief medical officer for prevention at the American Heart Association. "Sleep is an important element to heart health and overall health, and it is important to continue to raise awareness of the positive health effects of quality sleep and to address the negative health consequences associated with poor sleep."

    The American Heart Association will provide resources at www.heart.org/en/health-topics/sleep-disorders that provide education on thinking more holistically about sleep health, including science-based articles focused on sleep disorders and cardiovascular comorbidities.

    About Jazz Pharmaceuticals

    Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is a global biopharmaceutical company dedicated to developing and commercializing life-changing medicines that transform the lives of patients with serious diseases - often with limited or no options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in key therapeutic areas. Our focus is in neuroscience, including sleep and movement disorders, and in oncology, including hematologic malignancies and solid tumors. We actively explore new options for patients including novel compounds, small molecule advancements, biologics and innovative delivery technologies. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in more than 90 countries. For more information, please visit www.jazzpharmaceuticals.com and follow @JazzPharma on Twitter.

    Media Contact:

    Jacqueline Kirby, Vice President, Corporate Affairs & Government Relations

    Ireland +353 1 697 2141         U.S. +1 215 867 4910

    Investor Contact:

    Kathee Littrell, Vice President, Investor Relations

    Ireland +353 1 634 7887         U.S. +1 650 496 2717

    References:

    1. Liu Y, Wheaton AG, Chapman DP, Cunningham TJ, Lu H, Croft JB. Prevalence of healthy sleep duration among adults — United States, 2014. MMWR Morb Mortal Wkly Rep. 2016;65:137-41.
    2. Centers for Disease Control and Prevention. How Much Sleep Do I Need? Available at: https://www.cdc.gov/sleep/about_sleep/how_much_sleep.html. Accessed August 2020.
    3. Makarem N, Castro-Diehl C, St-Onge MP. Abstract 36: The Role of Sleep as a Cardiovascular Health Metric: Does It Improve Cardiovascular Disease Risk Prediction? Results From The Multi-Ethnic Study of Atherosclerosis. Circulation. 2020; 141(1).
    4. Grandner MA, Jackson NJ, Pak VM, Gehrman PR. Sleep disturbance is associated with cardiovascular and metabolic disorders. J Sleep Res. 2012;21(4):427-433. doi:10.1111/j.1365-2869.2011.00990.
    5. U.S. Department of Health and Human Services. MyHealthfinder: Get Enough Sleep. The Basics: Health Benefits. Available at: https://health.gov/myhealthfinder/topics/everyday-healthy-living/mental-health-and-relationships/get-enough-sleep#panel-2. Accessed August 2020.

    Jazz Pharmaceuticals Logo (PRNewsFoto/Jazz Pharmaceuticals plc) (PRNewsFoto/Jazz Pharmaceuticals plc)

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/jazz-pharmaceuticals-announces-new-sleep-health-collaboration-301131138.html

    SOURCE Jazz Pharmaceuticals plc

    View Full Article Hide Full Article
  3. DUBLIN, Sept. 9, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that the company has signed a new research collaboration agreement with Redx Pharma plc (AIM: REDX) to discover and develop drug candidates for two cancer targets in the Ras/Raf/MAP kinase (MAPK) pathway.  This research collaboration follows the previously announced sale of Redx's pre-clinical pan-RAF inhibitor program to Jazz for the potential treatment of Raf and Ras mutant tumors in July 2019. 

    Under the terms of the research collaboration agreement, Jazz will make an upfront payment to Redx of $10 million followed by another $10 million in year two, provided research work is continuing.  Following delivery of an IND-ready molecule, Redx will be…

    DUBLIN, Sept. 9, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that the company has signed a new research collaboration agreement with Redx Pharma plc (AIM: REDX) to discover and develop drug candidates for two cancer targets in the Ras/Raf/MAP kinase (MAPK) pathway.  This research collaboration follows the previously announced sale of Redx's pre-clinical pan-RAF inhibitor program to Jazz for the potential treatment of Raf and Ras mutant tumors in July 2019. 

    Under the terms of the research collaboration agreement, Jazz will make an upfront payment to Redx of $10 million followed by another $10 million in year two, provided research work is continuing.  Following delivery of an IND-ready molecule, Redx will be eligible to receive up to a further $200 million from Jazz in development, regulatory and commercial milestone payments for each program. The first milestone is payable upon successful investigational new drug (IND) application submission.  In addition, Redx is eligible to receive tiered royalties in mid-single digit percentages of any future net sales.  Following a successful submission of an IND application, Jazz will be responsible for further development, manufacturing, regulatory activities and commercialization.

    "We are excited to collaborate with Redx on two oncology programs in the Ras/Raf/MAP kinase pathway.  Redx has established itself as a strong partner for Jazz, given the continued momentum in our existing collaboration on Pan-RAF, and we look forward to this new collaboration and access to Redx's small molecule discovery capabilities," said Robert Iannone, M.D., M.S.C.E., executive vice president, research and development of Jazz Pharmaceuticals.  "We are strategically targeting this cancer pathway with multiple experimental approaches while further strengthening our targeted oncology pipeline. These programs in the Ras/Raf/MAP kinase pathway are highly complementary to our growing R&D portfolio of innovative and targeted oncology therapies."

    About Jazz Pharmaceuticals plc

    Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is a global biopharmaceutical company dedicated to developing and commercializing life-changing medicines that transform the lives of patients with serious diseases - often with limited or no options.  We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in key therapeutic areas. Our focus is in neuroscience, including sleep and movement disorders, and in oncology, including hematologic and solid tumors.  We actively explore new options for patients including novel compounds, small molecule advancements, biologics and innovative delivery technologies. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in more than 90 countries. For more information, please visit www.jazzpharmaceuticals.com and follow @JazzPharma on Twitter.

    "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995

    This press release contains forward-looking statements, including, but not limited to, statements related to the potential successful submission of an investigational new drug application and future development, manufacturing, regulatory and commercialization activities; potential future payments by Jazz Pharmaceuticals to Redx for development, regulatory and commercial milestones as well as tiered royalties based on future net sales; and other statements that are not historical facts.  These forward-looking statements are based on Jazz Pharmaceuticals' current plans, objectives, estimates, expectations and intentions and inherently involve significant risks and uncertainties.  Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with: Jazz Pharmaceuticals' ability to achieve the expected benefits (commercial or otherwise) from the research collaboration agreement; pharmaceutical product development and clinical success thereof; the regulatory approval process; effectively commercializing any product candidates; and other risks and uncertainties affecting Jazz Pharmaceuticals, including those described from time to time under the caption "Risk Factors" and elsewhere in Jazz Pharmaceuticals plc's Securities and Exchange Commission filings and reports (Commission File No. 001-33500), including Jazz Pharmaceuticals' Quarterly Report on Form 10-Q for the quarter ended June 30, 2020 and future filings and reports by Jazz Pharmaceuticals.  Other risks and uncertainties of which Jazz Pharmaceuticals is not currently aware may also affect Jazz Pharmaceuticals' forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated.  The forward-looking statements herein are made only as of the date hereof or as of the dates indicated in the forward-looking statements, even if they are subsequently made available by Jazz Pharmaceuticals on its website or otherwise.  Jazz Pharmaceuticals undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made.

    Jazz Pharmaceuticals Contacts:

    Investors:

    Kathee Littrell

    Vice President, Investor Relations

    Ireland, +353 1 634 7887

    U.S., +1 650 496 2717

     

    Media: 

    Jacqueline Kirby

    Vice President, Corporate Affairs & Government Relations

    Ireland, +353 1 697 2141

    U.S., +1 215 867 4910

     

    Jazz Pharmaceuticals Logo (PRNewsFoto/Jazz Pharmaceuticals plc) (PRNewsFoto/Jazz Pharmaceuticals plc)

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/jazz-pharmaceuticals-announces-new-research-collaboration-with-redx-pharma-to-discover-and-develop-two-targeted-cancer-therapies-301126080.html

    SOURCE Jazz Pharmaceuticals plc

    View Full Article Hide Full Article
  4. DUBLIN, Sept. 8, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that the company will webcast its corporate presentations at the following virtual investor conferences:

    • Morgan Stanley Global Healthcare Conference on Tuesday, September 15, 2020 at 2:45 p.m. EDT / 7:45 p.m. ISTBruce Cozadd, chairman and chief executive officer, will provide an overview of the company and a business and financial update.
       
    • Cantor Global Healthcare Conference on Wednesday, September 16, 2020 at 1:20 p.m. EDT / 6:20 p.m. ISTBruce Cozadd, chairman and chief executive officer, will provide an overview of the company and a business and financial update.
       
    • BofA Global Healthcare Conference on Friday, September 18, 2020 at 4:45 p.m.

    DUBLIN, Sept. 8, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that the company will webcast its corporate presentations at the following virtual investor conferences:

    • Morgan Stanley Global Healthcare Conference on Tuesday, September 15, 2020 at 2:45 p.m. EDT / 7:45 p.m. ISTBruce Cozadd, chairman and chief executive officer, will provide an overview of the company and a business and financial update.

       
    • Cantor Global Healthcare Conference on Wednesday, September 16, 2020 at 1:20 p.m. EDT / 6:20 p.m. ISTBruce Cozadd, chairman and chief executive officer, will provide an overview of the company and a business and financial update.

       
    • BofA Global Healthcare Conference on Friday, September 18, 2020 at 4:45 p.m. BST / IST.  Daniel Swisher, president and chief operating officer, will provide an overview of the company and a business and financial update.

    A live audio webcast of each presentation may be accessed from the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com.  Please connect to the website prior to the start of each presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast.

    An archive of each webcast will be available for at least one week following each presentation on the Investors section of the company's website at www.jazzpharmaceuticals.com.

    About Jazz Pharmaceuticals

    Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is a global biopharmaceutical company dedicated to developing and commercializing life-changing medicines that transform the lives of patients with serious diseases — often with limited or no options.  We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in key therapeutic areas.  Our focus is in neuroscience, including sleep medicine and movement disorders, and in oncology, including hematologic malignancies and solid tumors. We actively explore new options for patients including novel compounds, small molecule advancements, biologics and innovative delivery technologies.  Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in more than 90 countries.  For more information, please visit www.jazzpharmaceuticals.com and follow @JazzPharma on Twitter.

     

    Jazz Pharmaceuticals Contacts:















    Investors: 

    Kathee Littrell

    Vice President, Investor Relations

    Ireland +353 1 634 7887

    U.S. +1 650 496 2717





    Media:

    Jacqueline Kirby

    Vice President, Corporate Affairs & Government Relations

    Ireland +353 1 697 2141

    U.S. +1 215 867 4910

     

    Jazz Pharmaceuticals Logo (PRNewsFoto/Jazz Pharmaceuticals plc) (PRNewsFoto/Jazz Pharmaceuticals plc)

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/jazz-pharmaceuticals-announces-participation-at-three-upcoming-virtual-investor-conferences-301125836.html

    SOURCE Jazz Pharmaceuticals plc

    View Full Article Hide Full Article
  5. NEW YORK, Sept. 4, 2020 /PRNewswire/ -- S&P Dow Jones Indices will make the following index adjustments to the S&P 500, S&P MidCap 400 and S&P SmallCap 600 to ensure each index more appropriately represents its market capitalization range. The changes will be effective prior to the open of trading on Monday, September 21, 2020 to coincide with the September quarterly rebalance:

    S&P MidCap 400 constituents Etsy Inc. (NASD:ETSY), Teradyne Inc. (NASD:TER), and Catalent Inc. (NYSE:CTLT) will move to the S&P 500, replacing H&R Block Inc. (NYSE:HRB) Coty Inc. (NYSE:COTY) and Kohl's Corp. (NYSE:KSS), all of which will move to the S&P MidCap 400.

    S&P SmallCap 600 constituents Wingstop Inc. (NASD:WING), Medpace Holdings Inc. (NASD:MEDP), and Fox Factory…

    NEW YORK, Sept. 4, 2020 /PRNewswire/ -- S&P Dow Jones Indices will make the following index adjustments to the S&P 500, S&P MidCap 400 and S&P SmallCap 600 to ensure each index more appropriately represents its market capitalization range. The changes will be effective prior to the open of trading on Monday, September 21, 2020 to coincide with the September quarterly rebalance:

    S&P MidCap 400 constituents Etsy Inc. (NASD:ETSY), Teradyne Inc. (NASD:TER), and Catalent Inc. (NYSE:CTLT) will move to the S&P 500, replacing H&R Block Inc. (NYSE:HRB) Coty Inc. (NYSE:COTY) and Kohl's Corp. (NYSE:KSS), all of which will move to the S&P MidCap 400.

    S&P SmallCap 600 constituents Wingstop Inc. (NASD:WING), Medpace Holdings Inc. (NASD:MEDP), and Fox Factory Holding Corp. (NASD:FOXF) will move to the S&P MidCap 400, replacing PBF Energy Inc. (NYSE:PBF), Allegheny Technologies Inc. (NYSE:ATI) and Mack-Cali Realty Corp. (NYSE:CLI), all of which will move to the S&P SmallCap 600.

    Jazz Pharmaceuticals plc (NASD:JAZZ) will replace Transocean Ltd (NYSE:RIG) in the S&P MidCap 400. Transocean is no longer representative of the mid-cap market space.

    Mr. Cooper Group Inc. (NASD:COOP) and R1 RCM Inc. (NASD:RCM) will replace Express Inc. (NYSE:EXPR) and Pennsylvania Real Estate (NYSE:PEI) respectively in the S&P SmallCap 600.  Express and Pennsylvania Real Estate are no longer representative of the small-cap market space.

    Following is a summary of the changes that will take place prior to the open of trading on the effective date:

    Effective Date

    Index Name      

    Action

    Company Name

    Ticker

    GICS Sector

    Sept. 21, 2020

    S&P 500

    Addition

    Etsy

    ETSY

    Consumer Discretionary

    Sept. 21, 2020

    S&P 500

    Addition

    Teradyne

    TER

    Information Technology

    Sept. 21, 2020

    S&P 500

    Addition

    Catalent

    CTLT

    Health Care

    Sept. 21, 2020

    S&P 500

    Deletion

    H&R Block

    HRB

    Consumer Discretionary

    Sept. 21, 2020

    S&P 500

    Deletion

    Coty

    COTY

    Consumer Staples

    Sept. 21, 2020

    S&P 500

    Deletion

    Kohl's

    KSS

    Consumer Discretionary

    Sept. 21, 2020

    S&P MidCap 400

    Addition

    H&R Block

    HRB

    Consumer Discretionary

    Sept. 21, 2020

    S&P MidCap 400

    Addition

    Coty

    COTY

    Consumer Staples

    Sept. 21, 2020

    S&P MidCap 400

    Addition

    Kohl's

    KSS

    Consumer Discretionary

    Sept. 21, 2020

    S&P MidCap 400

    Addition

    Jazz Pharmaceuticals

    JAZZ

    Health Care

    Sept. 21, 2020

    S&P MidCap 400

    Addition

    Wingstop

    WING

    Consumer Discretionary

    Sept. 21, 2020

    S&P MidCap 400

    Addition

    Medpace Holdings

    MEDP

    Health Care

    Sept. 21, 2020

    S&P MidCap 400

    Addition

    Fox Factory Holding

    FOXF

    Consumer Discretionary

    Sept. 21, 2020

    S&P MidCap 400

    Deletion

    Etsy

    ETSY

    Consumer Discretionary

    Sept. 21, 2020

    S&P MidCap 400

    Deletion

    Teradyne

    TER

    Information Technology

    Sept. 21, 2020

    S&P MidCap 400

    Deletion

    Catalent

    CTLT

    Health Care

    Sept. 21, 2020

    S&P MidCap 400

    Deletion

    Transocean

    RIG

    Energy

    Sept. 21, 2020

    S&P MidCap 400

    Deletion

    PBF Energy

    PBF

    Energy

    Sept. 21, 2020

    S&P MidCap 400

    Deletion

    Allegheny Technologies

    ATI

    Materials

    Sept. 21, 2020

    S&P MidCap 400

    Deletion

    Mack-Cali Realty

    CLI

    Real Estate

    Sept. 21, 2020

    S&P SmallCap 600

    Addition

    PBF Energy

    PBF

    Energy

    Sept. 21, 2020

    S&P SmallCap 600

    Addition

    Allegheny Technologies

    ATI

    Materials

    Sept. 21, 2020

    S&P SmallCap 600

    Addition

    Mack-Cali Realty

    CLI

    Real Estate

    Sept. 21, 2020

    S&P SmallCap 600

    Addition

    Mr. Cooper Group

    COOP

    Financials

    Sept. 21, 2020

    S&P SmallCap 600

    Addition

    R1 RCM

    RCM

    Health Care

    Sept. 21, 2020

    S&P SmallCap 600

    Deletion

    Express

    EXPR

    Consumer Discretionary

    Sept. 21, 2020

    S&P SmallCap 600

    Deletion

    Pennsylvania Real Estate

    PEI

    Real Estate

    Sept. 21, 2020

    S&P SmallCap 600

    Deletion

    Wingstop

    WING

    Consumer Discretionary

    Sept. 21, 2020

    S&P SmallCap 600

    Deletion

    Medpace Holdings

    MEDP

    Health Care

    Sept. 21, 2020

    S&P SmallCap 600

    Deletion

    Fox Factory Holding

    FOXF

    Consumer Discretionary

    For more information about S&P Dow Jones Indices, please visit www.spdji.com

    ABOUT S&P DOW JONES INDICES

    S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P DJI has been innovating and developing indices across the spectrum of asset classes helping to define the way investors measure and trade the markets.

    S&P Dow Jones Indices is a division of S&P Global (NYSE:SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spdji.com.

    FOR MORE INFORMATION:

    S&P Dow Jones Indices

    Media Inquiries

    Cision View original content:http://www.prnewswire.com/news-releases/etsy-teradyne-and-catalent-set-to-join-sp-500-others-to-join-sp-midcap-400-and-sp-smallcap-600-301124693.html

    SOURCE S&P Dow Jones Indices

    View Full Article Hide Full Article
View All Jazz Pharmaceuticals plc News